The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis

Background: Chronic kidney disease (CKD) is a global public health problem, and anemia is a common complication in CKD patients. Roxadustat (FG-4592) is an oral hypoxia-inducible factor (HIF) stabilizer. Roxadustat has been shown in studies to keep up with and increase hemoglobin better than placebo...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Lijun Wang, Heng Yin, Liling Yang, Fenglian Zhang, Song Wang, Dan Liao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Subjects:	Anemia chronic kidney disease meta-analysis roxadustat CKD FG-4592
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.779694/full

Similar Items

Roxadustat for the treatment of anemia in patients with chronic kidney disease: a Meta-analysis
by: WANG Rui, et al.
Published: (2019-01-01)

The Efficacy and Safety of Roxadustat for Anemia in Hemodialysis Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials
by: Yunling Geng, et al.
Published: (2024-11-01)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
by: Qiaoqiao Zhou, et al.
Published: (2023-12-01)

Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation
by: A-Feng Miao, et al.
Published: (2021-01-01)

Roxadustat for the Treatment of Early Post-Transplantation Anemia
by: Louis Guenal, et al.
Published: (2025-10-01)

Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials
by: Xiaoyu Luo, et al.
Published: (2024-02-01)

Randomized Trial of Lower-Dose Roxadustat Efficacy and Safety in Non–Dialysis-Dependent CKD-Associated Anemia
by: Ping Li, et al.
Published: (2025-04-01)

Safety of Roxadustat in Chronic Kidney Disease Patients: An Updated Systematic Review and Meta-Analysis
by: Patricia Martínez-Miguel, et al.
Published: (2025-10-01)

Activation of Intestinal HIF2α Ameliorates Iron‐Refractory Anemia
by: Yingying Yu, et al.
Published: (2024-03-01)

Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis
by: Shan Chong, et al.
Published: (2022-09-01)

Roxadustat on Renal Anemia with Macroinflammation: A Retrospective Cohort Study
by: Yan Tu, et al.
Published: (2024-03-01)

Roxadustat: Not just for anemia
by: Xiaoyu Zhu, et al.
Published: (2022-08-01)

Treatment of anemia of chronic kidney disease caused by ANCA associated vasculitis with roxadustat:one case report with a literature review
by: Xiao Xiang, et al.
Published: (2021-01-01)

The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study
by: Weiwei Kong, et al.
Published: (2024-06-01)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
by: Keiji Hirai, et al.
Published: (2023-02-01)

Roxadustat for Patients with Posttransplant Anemia: A Narrative Review
by: Xiaoxiao Tang, et al.
Published: (2023-11-01)

Roxadustat promotes allograft recovery after kidney transplantation: A prospective, multicenter, randomized controlled trial
by: Mao-Lin Ma, et al.
Published: (2025-08-01)

Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
by: Lei Tian, et al.
Published: (2024-12-01)

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients
by: Wenhui Wu, et al.
Published: (2024-12-01)

Research progress on roxadustat treatment for renal anemia
by: HU Bao-li, HU Bin
Published: (2022-09-01)

FG-4592 relieves diabetic kidney disease severity by influencing metabolic profiles via gut microbiota reconstruction in both human and mouse models
by: Yumin Jiang, et al.
Published: (2023-08-01)

The role of roxadustat in chronic kidney disease patients complicated with anemia
by: Jie Liu, et al.
Published: (2023-03-01)

Case report: Roxadustat overdose in an anemia patient of chronic kidney disease: insight beyond insignificant consequence
by: Long-Guang Zhang, et al.
Published: (2024-08-01)

Impact of roxadustat on anemia management in infected patients undergoing long-term dialysis: a retrospective cohort analysis
by: Lulu Wang, et al.
Published: (2025-10-01)

Thyroid function analysis after roxadustat or erythropoietin treatment in patients with renal anemia: a cohort study
by: Xiaomeng Zheng, et al.
Published: (2023-12-01)

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia
by: Tian Xu, et al.
Published: (2025-12-01)

Cardiovascular Protective Effects of Oral Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat in the Treatment of Type 4 Cardiorenal-Anemia Syndrome: Protocol of a Randomized Controlled Trial
by: Yumin Wen, et al.
Published: (2022-04-01)

Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease
by: Chiara Bini, et al.
Published: (2024-09-01)

Research advances of roxadustat in the treatment of various diseases
by: Tian Qian-qian, et al.
Published: (2022-07-01)

Treatment of pure red cell aplasia in a chronic kidney disease patient with roxadustat: A case report
by: Liu Shanlin, et al.
Published: (2025-10-01)

Effectiveness and Safety of Roxadustat for Renal Anemia in Dialysis-dependent Chronic Kidney Disease: a Meta-analysis
by: LI Jiaqing, YANG Qing, YUAN Dunlu, HUANG Jingjing, CHANG Qing, NIE Jingwen, ZHOU Zhu, LI Qing
Published: (2023-02-01)

Assessment of the safety of Roxadustat for cardiovascular events in chronic kidney disease-related anemia using meta-analysis and bioinformatics
by: Xiangmeng Li, et al.
Published: (2024-06-01)

Roxadustat for ESA‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review
by: Meng Zhang, et al.
Published: (2025-10-01)

A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
by: Jie Liu, et al.
Published: (2024-05-01)

Roxadustat: Do we know all the answers?
by: Qiu-Yu Li, et al.
Published: (2023-05-01)

FG-4592 protects the intestine from irradiation-induced injury by targeting the TLR4 signaling pathway
by: Zhenlan Feng, et al.
Published: (2022-06-01)

Inhibition of OGFOD1 by FG4592 confers neuroprotection by activating unfolded protein response and autophagy after ischemic stroke
by: Jian Xie, et al.
Published: (2024-03-01)

Clinical efficacy and safety analysis in initial hemodialysis patient with renal anemia treated by roxadustat or recombinant human erythropoietin
by: Zhang Peng-jie, et al.
Published: (2022-11-01)

The Roxadustat (FG-4592) ameliorates tubulointerstitial fibrosis by promoting intact FGF23 cleavage
by: Jing Wang, et al.
Published: (2025-04-01)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
by: Zhikai Yang, et al.
Published: (2022-03-01)